Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer

Oncology

Volumn 55, Issue 2, 1998, Pages 152-160

  Allgayer, Heike ^a   Babic, Rudolf ^b   Beyer, Bianca C M ^a   Grützner, Klaus Uwe ^a   Tarabichi, Anwar ^a   Schildberg, Friedrich Wilhelm ^a   Heiss, Markus Maria ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Institute of Pathology and Cytology   (Germany)

Author keywords

Collagenase IV, 72 kD; Gastric cancer; Immunohistochemistry; MMP 2; Prognosis

Indexed keywords

GELATINASE A; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; STOMACH CANCER; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0031962081     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011850     Document Type: Article

References (36)

1. Dvorak HF: Tumors: Wounds that do not heal. N Engl J Med 1986;315:1650-1659.
2. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991;64:327-336.
3. Bond JS: Overview on protease classes, clans, and families. Proc AACR Spec Conf Proteases Protease Inhibitors, Panama City, March 1996.
4. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-68.
5. Chen WT: Membrane proteases: Roles in tissue remodeling and tumor invasion. Curr Opin Cell Biol 1992;4:802-809.
6. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Margulies IMK, Liotta LA: The activation of human type IV collagenase proenzyme. J Biol Chem 1989;264:1353-1356.
7. Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992;10:145-155.
8. Schmitt M, Jänicke F, Graeff H: Tumor-associated proteases. Fibrinolysis 1992;6(suppl 4):3-26.
9. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994;370:61-65.
10. Stetler-Stevenson WG, Krutzsch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2): A new member of the metalloproteinase inhibitor family. J Biol Chem 1989;264: 17374-17378.
11. Emmert-Buck MR, Emonard HP, Corcoran ML, Krutzsch HC, Foidart JM, Stetler-Stevenson WG: Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett 1995;364:28-32.
12. Blasi F: Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993;15: 105-111.
13. Gress TM, Müller-Pillasch F, Lerch MM, Friess H, Büchler H, Adler G: Expression and in-situ-localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995;62:407-413.
14. Nomura H, Sato H, Seiki M, Mai M, Okada Y: Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995;55:3263-3266.
15. Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y: Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer (Pred Oncol) 1996;69:9-16.
16. David L, Nesland JM, Holm R, Sobrinho-Simoes M: Expression of laminin, collagen IV, fibronectin, and type IV collagenase in gastric carcinoma: An immunohistochemical study of 87 patients. Cancer 1994;73:518-527.
17. Nuovo GJ, MacConnell PB, Simsir A, Valea F, French DL: Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995;55:267-275.
18. Höyhtyä M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA, Liang CM: Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994;56: 500-505.
19. Onisto M, Riccio MP, Scannapieco P, Caenazzo C, Griggio L, Spina M, Stetler-Stevenson WG, Garbisa S: Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. Int J Cancer 1995;63:621-626.
20. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993;67: 1126-1131.
21. Schwartz GK, Wang H, Lampen N, Altorki N, Kelsen D, Albino AP: Defining the invasive phenotype of proximal gastric cancer cells. Cancer 1994;73:22-27.
22. Fridman R, Toth M, Pena D, Mobashery S: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995;55:2548-2555.
23. Grigioni WF, D'Errico A, Fortunato C, Fiorentino M, Mancini AM, Stetler-Stevenson WG, Sobel ME, Liotta LA, Onisto M, Garbisa S: Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol 1994;7:220-225.
24. Heiss MM, Babic R, Allgayer H, Grützner KU, Jauch KW, Löhrs U, Schildberg FW: Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995;13:2084-2093.
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
26. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;37:1-39.
27. Cox DR: Regression models and life tables. J Stat Soc (B) 1972;34:187-220.
28. Laurén R: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal type carcinoma. Act Pathol Microbiol Scand 1965;64:31-34.
29. r 72,000 type IV collagenase. Cancer Res 1992;52:5845-5848.
30. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC, Fridman R: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996;56:1654-1659.
31. Moller LB: Structure and function of the urokinase receptor. Blood Coagul Fibrinolysis 1993; 4:293-303.
32. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hoefler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
33. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly J J, Andreasen, P: Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-6829.
34. Hollas W, Blasi F, Boyd D: Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 1991;51:3690-3695.
35. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Dano K: The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991;51:4067-4071.
36. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F, Dano K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-1067.